If you’ve ever sat waiting at the doctor’s office to give a blood sample, you might have wished there was a way to find the same information without needles.

But for all the medical breakthroughs of the 20th century, the best way to detect molecules has remained through liquids, such as blood. New research from the University of Chicago, however, could someday put a pause on pinpricks. A group of scientists announced they have created a small, portable device that can collect and detect airborne molecules—a breakthrough that holds promise for many areas of medicine and public health.

The researchers envision the device, nicknamed ABLE, could detect airborne viruses or bacteria in hospital or public spaces, improve neonatal care or allow people with diabetes to read glucose levels from their breath. The entire device is just four by eight inches across.

Portable tech captures molecules in breath to aid medical care from diabetes to at-risk newborn development.

A biophysical model sheds light on how the subtle interplay of fluid dynamics and bacterial growth controls the fluctuating population of microbes in the human gut.

The human body harbors large numbers of bacteria—about as many as human cells—most of which are located in the gut, mainly in the colon. Together, diverse microorganisms including multiple species and strains of bacteria constitute the gut microbiota, which is thought to play a central role in human health, affecting the immune response and the progression of different diseases. However, despite a vast body of microbiota studies based on gene sequencing and on experiments with animal models, the dynamics of microbial populations in the human gut remain poorly understood. Alinaghi Salari of the University of Toronto and James Cremer of Stanford University have now proposed a biophysical model of the gut environment that incorporates a broad set of features of the human large intestine [1].

The COVID-19 pandemic yielded important advances in testing for respiratory viruses, but it also exposed important unmet needs in screening to prevent the spread of infections in high-risk settings.

While PCR (polymerase chain reaction) tests are the gold standard for detecting viral infections, they remain a challenge for screening large numbers of people in places vulnerable to outbreaks—such as health care centers and nursing homes—due to high costs and the fact that different tests are required for each virus.

A new Yale study, however, finds that an alternate strategy—using a nasal swab to screen for an antiviral protein produced by the body as a defense against infection—can be an effective method for ruling out respiratory infections, limiting PCR testing only to those most likely to be infected, at a fraction of the cost.